Rx Patent Litigation Relates Mostly To Formulation, Use Patents, FTC Says
Executive Summary
A majority of drug patent challenges involve patents that do not cover the active ingredient, Federal Trade Commission Chairman Timothy Muris told a Senate Commerce Committee hearing on generic drugs April 23
You may also be interested in...
Generic Delay Tactics Evolving In Wake Of Consent Decrees – Initial FTC Data
Potentially anticompetitive strategies on generics have evolved since the Federal Trade Commission began imposing consent agreements on companies that made questionable settlements, FTC states
FTC/Biovail Tiazac Settlement Blocks Royalties From Andrx On Generic
The Federal Trade Commission consent order with Biovail regarding Tiazac voids a proposed settlement between the company and Andrx
FTC/Biovail Tiazac Settlement Blocks Royalties From Andrx On Generic
The Federal Trade Commission consent order with Biovail regarding Tiazac voids a proposed settlement between the company and Andrx